Duvelisib is a dual phosphoinositide-3-kinase (PI3K) delta and PI3K gamma inhibitor. The delta and gamma isozymes are selectively expressed in leukocytes. This article (at Dr. Melvin Crasto’s blog newdrugapprovals.org) discusses the synthesis of Duvelisib and mentions additional clinical trials underway including a phase II trial for the treatment of patients with mild asthma undergoing allergen challenge, for the treatment of rheumatoid arthritis and for the treatment of refractory indolent non-Hodgkin’s lymphoma. Phase I clinical trials for the treatment of advanced hematological malignancies (including T-cell lymphoma and mantle cell lymphoma). The drug was originally developed at Takeda subsidiary Intellikine.
Infinity and AbbVie partner to develop and commercialise Duvelisib for cancer… for the treatment of chronic lymphocytic leukemia
November 8, 2014 by sjwilliamspa
Leave a Reply